Pfizer Inc (PFE)

Currency in USD
27.16
+0.35(+1.31%)
Closed·
27.09-0.07(-0.26%)
·
High dividend Yield
PFE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.5327.29
52 wk Range
20.9227.94
Key Statistics
Prev. Close
26.81
Open
26.82
Day's Range
26.53-27.29
52 wk Range
20.92-27.94
Volume
37.74M
Average Vol. (3m)
47.39M
1-Year Change
1.952%
Book Value / Share
15.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PFE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.43
Upside
+4.66%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 15 consecutive years

Pfizer Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Employees
75000

Pfizer Inc SWOT Analysis


Valuation Insights
With a consensus 'Hold' rating and price targets ranging from $24 to $30, Pfizer's current stock price of $24.5 suggests potential undervaluation in the market
Regulatory Headwinds
Navigate the impact of healthcare reforms and the Inflation Reduction Act on Pfizer's operations, including an $825 million hit in Q2 2025 from Medicare Part D changes
Financial Resilience
Despite market challenges, Pfizer maintains strong profitability with a 73.8% gross profit margin and a 7.15% dividend yield, signaling long-term financial stability
Oncology Ambitions
Pfizer's strategic focus on oncology, bolstered by acquisitions and pipeline developments, aims to offset challenges from patent expirations and drive future growth
Read full SWOT analysis

Pfizer Inc Earnings Call Summary for Q4/2025

  • Pfizer reported Q4 2025 EPS of $0.66, beating forecasts by 13.79%, with revenue of $17.6 billion; despite this, stock fell 4.54% in pre-market trading.
  • Full-year 2025 revenue reached $62.6 billion (2% operational decline), while adjusted diluted EPS rose to $3.22 from $3.11 last year.
  • For 2026, Pfizer projects revenue between $59.5-62.5 billion and adjusted EPS of $2.80-3.00, with COVID product revenues expected to decline to $5 billion.
  • Cost-saving initiatives are targeted to yield $5.7 billion by 2026, as the company focuses on strategic R&D investments and AI implementation to improve productivity.
  • CEO Albert Bourla called 2026 'an important year in a pivotal investment period,' while analysts expressed concerns about declining COVID revenues and growth sustainability.
Last Updated: 02/03/2026, 11:39 AM
Read Full Transcript
Pfizer investor slides for Q4/2025
Pfizer Q4 2025 slides
Last Update: Feb 03, 2026
See full investor slides

Compare PFE to Peers and Sector

Metrics to compare
PFE
Peers
Sector
Relationship
P/E Ratio
20.0x22.4x−0.5x
PEG Ratio
−5.840.430.00
Price / Book
1.8x1.5x2.6x
Price / LTM Sales
2.5x2.3x3.2x
Upside (Analyst Target)
0.7%0.0%51.4%
Fair Value Upside
Unlock12.1%7.1%Unlock

Analyst Ratings

10 Buy
15 Hold
3 Sell
Ratings:
28 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 28.43
(+4.66% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BMO Capital
Buy30.00+10.46%-MaintainMar 09, 2026
Argus
Buy35.00+28.87%-UpgradeMar 02, 2026
RBC Capital
Sell25.00-7.95%-New CoverageFeb 24, 2026
Barclays
Sell25.00-7.95%-New CoverageFeb 19, 2026
Daiwa Securities
Hold27.00-0.59%-DowngradeFeb 12, 2026

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.36%
Dividend Yield
6.42%
Industry Median 2.37%
Annualized Payout
1.72
Paid quarterly
5-Years Growth
+2.50%
Growth Streak

Earnings

Latest Release
Feb 03, 2026
EPS / Forecast
0.66 / 0.58
Revenue / Forecast
17.58B / 16.91B
EPS Revisions
Last 90 days

PFE Income Statement

People Also Watch

403.11
MU
+3.54%
288.69
JPM
-0.42%
184.76
NVDA
+1.16%
347.08
TSM
-0.46%
342.52
AVGO
-0.93%

FAQ

What Is the Pfizer (PFE) Stock Price Today?

The Pfizer stock price today is 27.16 USD.

What Stock Exchange Does Pfizer Trade On?

Pfizer is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Pfizer?

The stock symbol for Pfizer is "PFE."

Does Pfizer Pay Dividends? What’s The Current Dividend Yield?

The Pfizer dividend yield is 6.42%.

What Is the Pfizer Market Cap?

As of today, Pfizer market cap is 154.04B USD.

What Is Pfizer's Earnings Per Share (TTM)?

The Pfizer EPS (TTM) is 1.36.

When Is the Next Pfizer Earnings Date?

Pfizer will release its next earnings report on May 05, 2026.

From a Technical Analysis Perspective, Is PFE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Pfizer Stock Split?

Pfizer has split 6 times.

How Many Employees Does Pfizer Have?

Pfizer has 75000 employees.

What is the current trading status of Pfizer (PFE)?

As of Mar 10, 2026, Pfizer (PFE) is trading at a price of 27.16 USD, with a previous close of 26.81 USD. The stock has fluctuated within a day range of 26.53 USD to 27.29 USD, while its 52-week range spans from 20.92 USD to 27.94 USD.

What Is Pfizer (PFE) Price Target According to Analysts?

The average 12-month price target for Pfizer is 28.43 USD, with a high estimate of 35.46 USD and a low estimate of 25 USD. 10 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an +4.66% Upside potential.

What Is the PFE Premarket Price?

PFE's last pre-market stock price is 26.80 USD. The pre-market share volume is 217,500.00, and the stock has decreased by -0.01, or -0.04%.

What Is the PFE After Hours Price?

PFE's last after hours stock price is 27.09 USD, the stock has decreased by -0.07, or -0.26%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.